Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1527 | Fiberoptic Endoscopic Evaluation of Swallowing Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003680 | Deglutition Disorders NIH | 0.41 |
| D002318 | Cardiovascular Diseases NIH | 0.17 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002015 | Dysphagia HPO | 0.41 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.17 |
Navigate: Correlations HPO
There is one clinical trial.
Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage. Supportive data exist for use of convalescent plasma in the treatment of COVID19 and other overwhelming viral illnesses. The study team wants to test the hypothesis that treatment with COVID19 CP will demonstrate salutary effects on COVID19 disease severity/duration, with the primary objective to reduce mortality. In addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation. This phase is to test the safety and efficacy of CP therapy.
Description: Change in mortality of high risk COVID 19 disease compared with the control arm
Measure: Change in mortality Time: until hospital discharge or a maximum of 60 days whichever comes firstDescription: Change in the duration of mechanical ventilation in high risk COVID 19 disease compared with the control arm
Measure: Change in requirement for mechanical ventilation Time: until hospital discharge or a maximum of 60 days whichever comes firstDescription: Change in the time a participant will remain on the ventilator
Measure: Change in the duration of mechanical ventilation Time: until hospital discharge or a maximum of 60 days whichever comes firstDescription: Incidence of Treatment-Emergent Adverse Events during study period
Measure: Incidence of Treatment-Emergent Adverse Events Time: Incidence of Treatment-Emergent Adverse Events until hospital discharge or a maximum of 60 days whichever comes firstAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports